Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

ABSTRACT:

Background

Chronic kidney disease (CKD) is largely driven by inflammation. Mesenchymal stem cells (MSCs) show therapeutic potential; however, their efficacy across CKD etiologies remains unclear.

Methods

Comprehensive searches were conducted in PubMed, Cochrane, ScienceDirect, Scopus and Google Scholar. Effect sizes for inflammation and renal function outcomes were meta-analyzed.

Results

Of 2514 studies screened, 52 met inclusion criteria (49 animal studies, 3 randomized controlled trials). In animal models, MSCs significantly reduced interleukin-6 (mean difference [MD] = -155.80; 95% CI: -249.10, -62.51; p = 0.001) and tumor necrosis factor-α (TNF-α) (MD = -35.53; 95% CI: -52.75, -18.30; p < 0.0001). In patients, TNF-α reduction was not significant (MD

SUBMITTER: Pura L 

PROVIDER: S-EPMC12428256 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature